Coronary disease & intervention

Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.

Steg et al. · Am Heart J · 2026 May 26

Read more

Single-cell transcriptomics reveals NDRG1/TGF‑β1 associated vascular smooth muscle cell phenotypic switching in chronic thromboembolic pulmonary hypertension.

Zheng et al. · J Thromb Thrombolysis · 2026 May 29

Explainable machine learning for estimation of elevated left ventricular filling pressure: a multicenter validation.

Nakamura et al. · J Echocardiogr · 2026 May 29

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors.

Bhatt et al. · JAMA Netw Open · 2026 May 1

Prevalence, pathogenesis, and clinical impact of pulmonary hypertension associated with chronic obstructive pulmonary disease.

Scabello et al. · Front Cardiovasc Med · 2026